The VA Is Testing MDMA as a Treatment for Veterans — Here's What You Need to Know

Shelley DeMarco
May 29
3 min read

For years, veterans struggling with PTSD and addiction have often felt like the existing treatments just weren't near enough. Now, the Department of Veterans Affairs is taking a notable step in a new direction — one that involves a substance most people still associate with nightclubs rather than clinical therapy.

The VA has launched a new clinical trial studying whether MDMA-assisted therapy could help veterans suffering from severe mental health conditions, including post-traumatic stress disorder and alcoholism. It's a development that's been years in the making, and one that a lot of people in the veteran mental health community are quietly hopeful about.

So What Exactly Is the Study?

The trial is officially titled "A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans," and it will enroll approximately 80 veterans. Researchers will compare outcomes between those receiving MDMA-assisted therapy and those receiving identical psychotherapy with an active placebo.

In other words, this isn't just about giving veterans MDMA and seeing what happens. The drug is being used as a companion to structured psychotherapy — the idea being that MDMA may help patients engage more openly and deeply with the therapeutic process itself.

Treatments will be delivered in a safe, controlled clinical setting using pharmaceutical-grade drugs, under careful quality controls and stringent safety protocols developed alongside the FDA.

The study began enrolling participants on May 18, with results expected in May 2030.

Where Is It Happening?

Approximately 80 veterans are expected to participate in the trial, receiving treatment at VA Providence Healthcare System, with participants recruited from the Providence, Rhode Island campus and VA Connecticut Healthcare System in West Haven, Connecticut.

The study was funded through a $1.5 million, five-year federal grant announced in December 2024.

Why PTSD and Alcohol Use Disorder?

That's actually one of the more interesting aspects of this particular study. PTSD and alcohol use disorder tend to show up together in veterans — one often feeding the other — yet they've traditionally been treated as separate problems requiring separate interventions.

Researchers are excited by the inclusion of alcohol use disorder alongside PTSD in the same study, seeing MDMA as a potential solution to tackling both conditions together in a population with high need for both.

Treating them in tandem, rather than sequentially, could represent a meaningful shift in how care is delivered to veterans dealing with compounding mental health challenges.

This Is Part of Something Bigger

This MDMA trial doesn't exist in a vacuum. The VA is currently involved in 19 active clinical trials focused on psychedelic therapies for mental health conditions, supported by more than $23 million in external funding.

The FDA has also granted breakthrough therapy designation to several psychedelic substances, including MDMA, psilocybin, and LSD, which allows for expedited review of these drugs. That designation signals that there's enough early promise in the research to warrant a faster path through the evaluation process.

What Veteran Organizations Are Saying

The response from major veteran advocacy groups has been warm. The Disabled American Veterans organization noted that far too many veterans continue to struggle with the invisible wounds of war, often after exhausting traditional treatment options, and called the study an important step forward in better understanding the role psychedelics could play in veteran mental health care.

That sentiment echoes what many veterans and their families have expressed privately for years — that the current toolkit of treatments, while valuable, doesn't work for everyone.

A Few Things to Keep in Mind

Researchers have noted some reasonable questions about the study's scope. Many veterans with the most severe or complex presentations may not qualify for the trial due to medication requirements and other eligibility restrictions, which raises questions about how broadly the eventual findings will apply to the real-world veteran population most in need.

And the VA has been straightforward in reminding veterans not to get ahead of the research. The VA strongly discourages self-medicating or attempting to replace other mental health treatment options with psychedelics or any other unprescribed substances, and emphasizes that veterans should always consult their health care providers before making any treatment decisions.

The Bottom Line

This is still early-stage research, and 2030 is a long way off. But for veterans who have felt stuck — who have tried the medications, done the therapy, and still can't get to a better place — the fact that the VA is seriously exploring new options is meaningful in itself.

Veterans deserve access to every safe, evidence-based tool that may help them heal. This study is a step toward figuring out whether MDMA-assisted therapy might become one of those tools.